Sign in
Taking peopleNo phase

Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
96 people, planned
Started
1 Jul 2025
Expected to end
1 Jul 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Normal saline
  • Oral melatonin syrup
  • Nebulized dexmedetomidine
Record updated
16 January 2026

Who can take part

Age
3 years to 7 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Children aged between 3 and 7 years
  • Both sexes
  • Classified as American Society of Anesthesiologists (ASA) physical status I or II according to the American Society of Anesthesiologists
  • Scheduled for elective adenotonsillectomy under general anesthesia

Who cannot take part

  • Current or recent treatment with anticonvulsants or sedative medications
  • Known allergy or hypersensitivity to dexmedetomidine, melatonin or midazolam
  • Central nervous system disorders
  • Neurological or psychiatric conditions associated with anxiety or agitation (e.g., cerebral palsy, epilepsy, separation anxiety disorder, attention-deficit/hyperactivity disorder)
  • Parental refusal to participate in the study
  • Presence of developmental delay
  • Intellectual disability (formerly termed mental retardation)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in Egypt.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to compare the efficacy of using oral Melatonin versus nebulized Dexmedetomidine in limitation of emergence agitation in children undergoing adenotonsillectomy.

The 3 groups in the trial

  • Group C (Control Group)Existing treatment, for comparison

    Participants will receive placebo nebulizer (3 ml of normal saline) without drug and 0.5 mg/kg of midazolam dissolved in Apple Juice.

    Treatment: Normal saline

  • Melatonin GroupTreatment being tested

    Participants will receive placebo nebulizer (3 ml of normal saline) without drug and 0.2 mg/kg of oral melatonin syrup.

    Treatment: Oral melatonin syrup

  • Dexmedetomidine GroupTreatment being tested

    Participants will receive placebo syrup (Apple Juice) and 2 µ/kg nebulized dexmedetomidine prepared in 0.9% normal saline to a final volume of 3ml.

    Treatment: Nebulized dexmedetomidine

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison Between Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy: A Prospective, Randomized Controlled Trial
Criteria questions
Built from NCT07345715, who can take part
Record updated
16 January 2026